{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:29:24Z","timestamp":1791595764761,"version":"4.3.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T00:00:00Z","timestamp":1646784000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T00:00:00Z","timestamp":1646784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Myelin Oligodendrocyte Glycoprotein antibody-associated disease (MOGAD) is most classically associated in both children and adults with phenotypes including bilateral and recurrent optic neuritis (ON) and transverse myelitis (TM), with the absence of brain lesions characteristic of multiple sclerosis (MS). ADEM phenotype is the most common presentation of MOGAD in children. However, the presence of clinical phenotypes including unilateral ON and short TM in some patients with MOGAD may lead to their misdiagnosis as MS. Thus, clinically and radiologically, MOGAD can mimic MS and clinical vigilance is required for accurate diagnostic workup.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We present three cases initially diagnosed as MS and then treated with alemtuzumab. Unexpectedly, all three patients did quite poorly on this medication, with a decline in their clinical status with worsening of expanded disability status scale (EDSS) and an increasing lesion load on magnetic resonance imaging of the brain. Subsequently, all three cases were found to have anti-MOG antibody in their serum.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These cases highlight that if a patient suspected to have MS does not respond to conventional treatments such as alemtuzumab, a search for alternative diagnoses such as MOG antibody disease may be warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-022-02612-6","type":"journal-article","created":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T06:03:11Z","timestamp":1646805791000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Failure of alemtuzumab therapy in three patients with MOG antibody associated disease"],"prefix":"10.1186","volume":"22","author":[{"given":"Sinali O.","family":"Seneviratne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Marriott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudarshini","family":"Ramanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Brilot-Turville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Butzkueven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6404-9768","authenticated-orcid":false,"given":"Mastura","family":"Monif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,9]]},"reference":[{"issue":"5","key":"2612_CR1","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.apjtb.2017.03.001","volume":"6","author":"KMM Koriem","year":"2016","unstructured":"Koriem KMM. Multiple sclerosis: New insights and trends. Asian Pacific Journal of Tropical Biomedicine. 2016;6(5):429\u201340. https:\/\/doi.org\/10.1016\/j.apjtb.2017.03.001.","journal-title":"Asian Pacific Journal of Tropical Biomedicine"},{"issue":"2","key":"2612_CR2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162\u201373. https:\/\/doi.org\/10.1016\/S1474-4422(17)30470-2.","journal-title":"Lancet Neurol"},{"issue":"1","key":"2612_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s13311-012-0159-0","volume":"10","author":"AJ Coles","year":"2013","unstructured":"Coles AJ. Alemtuzumab Therapy for Multiple Sclerosis. Neurotherapeutics. 2013;10(1):29\u201333. https:\/\/doi.org\/10.1007\/s13311-012-0159-0.","journal-title":"Neurotherapeutics"},{"issue":"17","key":"2612_CR4","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","volume":"359","author":"AJ Coles","year":"2008","unstructured":"Coles AJ, Compston DAS, Selmaj KW, Lake SL, Moran S, Margolin DH, et al. Alemtuzumab vs. Interferon beta-1a in early multiple sclerosis. New England Journal of Medicine. 2008;359(17):1786\u2013801.","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"2612_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40360-018-0267-5","volume":"19","author":"AZ Myro","year":"2018","unstructured":"Myro AZ, Bjerke G, Zarnovicky S, Holmoy T. Diffuse alveolar hemorrhage during alemtuzumab infusion in a patient with multiple sclerosis: a case report. Bmc Pharmacology & Toxicology. 2018;19(1):1\u20134. https:\/\/doi.org\/10.1186\/s40360-018-0267-5.","journal-title":"Bmc Pharmacology & Toxicology"},{"key":"2612_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.671425","volume":"12","author":"Y Zheng","year":"2021","unstructured":"Zheng Y, Cai MT, Li EC, Fang W, Shen CH, Zhang YX. Case Report: Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorder Masquerading as Multiple Sclerosis: An Under-Recognized Entity? Front Immunol. 2021;12: 671425. https:\/\/doi.org\/10.3389\/fimmu.2021.671425.","journal-title":"Front Immunol"},{"issue":"2","key":"2612_CR7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","volume":"89","author":"S Ramanathan","year":"2018","unstructured":"Ramanathan S, Mohammad S, Tantsis E, Nguyen TK, Merheb V, Fung VSC, et al. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry. 2018;89(2):127\u201337. https:\/\/doi.org\/10.1136\/jnnp-2017-316880.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2612_CR8","doi-asserted-by":"publisher","first-page":"175628641876208","DOI":"10.1177\/1756286418762083","volume":"11","author":"MS Weber","year":"2018","unstructured":"Weber MS, Derfuss T, Metz I, Bruck W. Defining distinct features of anti-MOG antibody associated central nervous system demyelination. Ther Adv Neurol Disord. 2018;11:1756286418762083. https:\/\/doi.org\/10.1177\/1756286418762083.","journal-title":"Ther Adv Neurol Disord"},{"key":"2612_CR9","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.msard.2018.07.025","volume":"25","author":"R Narayan","year":"2018","unstructured":"Narayan R, Simpson A, Fritsche K, Salama S, Pardo S, Mealy M, et al. MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2018;25:66\u201372. https:\/\/doi.org\/10.1016\/j.msard.2018.07.025.","journal-title":"Mult Scler Relat Disord"},{"key":"2612_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13641","author":"F Bartels","year":"2021","unstructured":"Bartels F, Lu A, Oertel FC, Finke C, Paul F, Chien C. Clinical and neuroimaging findings in MOGAD-MRI and OCT. Clin Exp Immunol. 2021. https:\/\/doi.org\/10.1111\/cei.13641.","journal-title":"Clin Exp Immunol"},{"issue":"14","key":"2612_CR11","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1177\/1352458519893093","volume":"26","author":"S Salama","year":"2020","unstructured":"Salama S, Khan M, Shanechi A, Levy M, Izbudak I. MRI differences between MOG antibody disease and AQP4 NMOSD. Mult Scler. 2020;26(14):1854\u201365. https:\/\/doi.org\/10.1177\/1352458519893093.","journal-title":"Mult Scler"},{"issue":"3","key":"2612_CR12","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/brain\/aww350","volume":"140","author":"M Jurynczyk","year":"2017","unstructured":"Jurynczyk M, Geraldes R, Probert F, Woodhall MR, Waters P, Tackley G, et al. Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis. Brain. 2017;140(3):617\u201327. https:\/\/doi.org\/10.1093\/brain\/aww350.","journal-title":"Brain"},{"issue":"4","key":"2612_CR13","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/1352458515593406","volume":"22","author":"S Ramanathan","year":"2016","unstructured":"Ramanathan S, Prelog K, Barnes EH, Tantsis EM, Reddel SW, Henderson AP, et al. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. Mult Scler. 2016;22(4):470\u201382. https:\/\/doi.org\/10.1177\/1352458515593406.","journal-title":"Mult Scler"},{"issue":"11","key":"2612_CR14","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1007\/s00415-018-8822-y","volume":"265","author":"V Devonshire","year":"2018","unstructured":"Devonshire V, Phillips R, Wass H, Da Roza G, Senior P. Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations. J Neurol. 2018;265(11):2494\u2013505. https:\/\/doi.org\/10.1007\/s00415-018-8822-y.","journal-title":"J Neurol"},{"issue":"8","key":"2612_CR15","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1177\/1352458519849511","volume":"26","author":"J Ciron","year":"2020","unstructured":"Ciron J, Cobo-Calvo A, Audoin B, Bourre B, Brassat D, Cohen M, et al. Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study. Mult Scler. 2020;26(8):936\u201344. https:\/\/doi.org\/10.1177\/1352458519849511.","journal-title":"Mult Scler"},{"issue":"5","key":"2612_CR16","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1007\/s00415-018-9122-2","volume":"266","author":"R Wynford-Thomas","year":"2019","unstructured":"Wynford-Thomas R, Jacob A, Tomassini V. Neurological update: MOG antibody disease. J Neurol. 2019;266(5):1280\u20136. https:\/\/doi.org\/10.1007\/s00415-018-9122-2.","journal-title":"J Neurol"},{"issue":"1","key":"2612_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-016-0718-0","volume":"13","author":"S Jarius","year":"2016","unstructured":"Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. Journal of Neuroinflammation. 2016;13(1):1\u201345. https:\/\/doi.org\/10.1186\/s12974-016-0718-0.","journal-title":"Journal of Neuroinflammation"},{"issue":"12","key":"2612_CR18","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1007\/s00115-018-0607-0","volume":"89","author":"S Jarius","year":"2018","unstructured":"Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. Nervenarzt. 2018;89(12):1388\u201399. https:\/\/doi.org\/10.1007\/s00115-018-0607-0.","journal-title":"Nervenarzt"},{"issue":"7","key":"2612_CR19","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1177\/1352458519845112","volume":"26","author":"CL de Mol","year":"2020","unstructured":"de Mol CL, Wong Y, van Pelt ED, Wokke B, Siepman T, Neuteboom RF, et al. The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults. Mult Scler. 2020;26(7):806\u201314. https:\/\/doi.org\/10.1177\/1352458519845112.","journal-title":"Mult Scler"},{"issue":"3","key":"2612_CR20","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00415-016-8360-4","volume":"264","author":"S Jarius","year":"2017","unstructured":"Jarius S, Eichhorn P, Franciotta D, Petereit HF, Akman-Demir G, Wick M, et al. The MRZ reaction as a highly specific marker of multiple sclerosis: re-evaluation and structured review of the literature. J Neurol. 2017;264(3):453\u201366. https:\/\/doi.org\/10.1007\/s00415-016-8360-4.","journal-title":"J Neurol"},{"issue":"2","key":"2612_CR21","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1212\/WNL.0000000000004087","volume":"89","author":"B Wildemann","year":"2017","unstructured":"Wildemann B, Jarius S, Schwarz A, Diem R, Viehover A, Hahnel S, et al. Failure of alemtuzumab therapy to control MOG encephalomyelitis. Neurology. 2017;89(2):207\u20139. https:\/\/doi.org\/10.1212\/WNL.0000000000004087.","journal-title":"Neurology"},{"issue":"2","key":"2612_CR22","doi-asserted-by":"publisher","first-page":"e111","DOI":"10.1212\/wnl.0000000000009758","volume":"95","author":"JJ Chen","year":"2020","unstructured":"Chen JJ, Flanagan EP, Bhatti MT, Jitprapaikulsan J, Dubey D, Lopez Chiriboga ASS, et al. Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology. 2020;95(2):e111\u201320. https:\/\/doi.org\/10.1212\/wnl.0000000000009758.","journal-title":"Neurology"},{"issue":"2","key":"2612_CR23","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1001\/jamaneurol.2013.598","volume":"70","author":"R Rudick","year":"2013","unstructured":"Rudick R, Polman C, Clifford D, Miller D, Steinman L. Natalizumab: bench to bedside and beyond. JAMA Neurol. 2013;70(2):172\u201382. https:\/\/doi.org\/10.1001\/jamaneurol.2013.598.","journal-title":"JAMA Neurol"},{"issue":"17","key":"2612_CR24","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1212\/01.wnl.0000327671.91357.96","volume":"71","author":"M Krumbholz","year":"2008","unstructured":"Krumbholz M, Meinl I, K\u00fcmpfel T, Hohlfeld R, Meinl E. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology. 2008;71(17):1350\u20134. https:\/\/doi.org\/10.1212\/01.wnl.0000327671.91357.96.","journal-title":"Neurology"},{"issue":"2","key":"2612_CR25","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1001\/archneurol.2011.216","volume":"69","author":"I Kleiter","year":"2012","unstructured":"Kleiter I, Hellwig K, Berthele A, K\u00fcmpfel T, Linker RA, Hartung HP, et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol. 2012;69(2):239\u201345. https:\/\/doi.org\/10.1001\/archneurol.2011.216.","journal-title":"Arch Neurol"},{"issue":"8","key":"2612_CR26","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1080\/14712598.2019.1611778","volume":"19","author":"M Ancau","year":"2019","unstructured":"Ancau M, Berthele A, Hemmer B. CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date. Expert Opin Biol Ther. 2019;19(8):829\u201343. https:\/\/doi.org\/10.1080\/14712598.2019.1611778.","journal-title":"Expert Opin Biol Ther"},{"key":"2612_CR27","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jns.2017.01.025","volume":"373","author":"M Cohen","year":"2017","unstructured":"Cohen M, Romero G, Bas J, Ticchioni M, Rosenthal M, Lacroix R, et al. Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: Results from a bicentric study. J Neurol Sci. 2017;373:335\u20138. https:\/\/doi.org\/10.1016\/j.jns.2017.01.025.","journal-title":"J Neurol Sci"},{"issue":"11","key":"2612_CR28","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","volume":"68","author":"SH Kim","year":"2011","unstructured":"Kim SH, Kim W, Li XF, Jung IJ, Kim HJ. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol. 2011;68(11):1412\u201320. https:\/\/doi.org\/10.1001\/archneurol.2011.154.","journal-title":"Arch Neurol"},{"key":"2612_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102251","volume":"44","author":"DH Whittam","year":"2020","unstructured":"Whittam DH, Cobo-Calvo A, Lopez-Chiriboga AS, Pardo S, Gornall M, Cicconi S, et al. Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. Mult Scler Relat Disord. 2020;44: 102251. https:\/\/doi.org\/10.1016\/j.msard.2020.102251.","journal-title":"Mult Scler Relat Disord"},{"key":"2612_CR30","doi-asserted-by":"publisher","unstructured":"Graf J, Mares J, Barnett M, Aktas O, Albrecht P, Zamvil SS, Hartung HP. Targeting B cells to modify MS, NMOSD, and MOGAD: Part 2. Neurol Neuroimmunol Neuroinflamm. 2020;8(1):e919. https:\/\/doi.org\/10.1212\/NXI.0000000000000919.","DOI":"10.1212\/NXI.0000000000000919"},{"key":"2612_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102696","volume":"48","author":"PM Elsbernd","year":"2021","unstructured":"Elsbernd PM, Hoffman WR, Carter JL, Wingerchuk DM. Interleukin-6 inhibition with tocilizumab for relapsing MOG-IgG associated disorder (MOGAD): A case-series and review. Mult Scler Relat Disord. 2021;48: 102696. https:\/\/doi.org\/10.1016\/j.msard.2020.102696.","journal-title":"Mult Scler Relat Disord"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02612-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-022-02612-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02612-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T06:03:12Z","timestamp":1646805792000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-022-02612-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,9]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2612"],"URL":"https:\/\/doi.org\/10.1186\/s12883-022-02612-6","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,9]]},"assertion":[{"value":"14 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Human Research Ethics Committee of Royal Melbourne Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication of data was obtained from the patients. A copy of the consent form is available for review by the Editor of the journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"84"}}